Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...

Contacts IR Contacts United States Ran Meir (267) 468-4475 Israel Yael Ashman 972 (3) 914-8262 PR Contacts United States Kelley Dougherty (973) 658-0237 Yonatan Beker (973) 264 7378 ...

Sandoz ® Lenalidomide is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q ...

1 Belada D, M.D., Ph.D., et al. A Phase 1b, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in ...

Data comparing long-term outcomes in lenalidomide-treated and untreated patients with myelodysplastic syndromes (MDS) with del (5q) are limited. We evaluated clinical outcomes of 295 lenalidomide ...

There was no difference in risk for lenalidomide plus cyclophosphamide, lenalidomide plus dexamethasone, and melphalan alone. "These data suggest that the future role of oral melphalan in ...

Editorial Lenalidomide in Myeloma — A High-Maintenance Friend Author: Ashraf Z. Badros, M.B., Ch.B. Author Info & Affiliations Published May 10, 2012 N Engl J Med 2012;366: 1836 - 1838 ...

Lenalidomide offers an exciting advance in the treatment of the 5q– MDS patient. It has the ability to alter the course of MDS by inducing hematologic and cytogenetic responses, resulting in ...

Lenalidomide may be used to treat patients with severe, treatment-refractory cutaneous lupus erythematosus, although the drug may not be advisable for patients with systemic disease, according to ...